Dr Reddy's Laboratories Faces Fifth Consecutive Day of Decline
Dr Reddys Laboratories Ltd drops for fifth straight session
Business Standard
Image: Business Standard
Dr Reddy's Laboratories Ltd shares fell by 0.1% to ₹1268.7, marking the fifth consecutive day of decline. Despite a 3.99% increase over the past year, the stock underperformed compared to the NIFTY index, which is up 0.54% today. The Nifty Pharma index, however, has shown a stronger performance with an 11.69% rise over the same period.
- 01Dr Reddy's Laboratories Ltd shares fell 0.1% today, continuing a five-day decline.
- 02The stock has gained 3.99% over the last year, underperforming the NIFTY index.
- 03The Nifty Pharma index increased by 11.69% in the past year.
- 04Trading volume for Dr Reddy's stock reached 77.06 lakh shares today, significantly above its monthly average.
- 05The stock's price-to-earnings (PE) ratio stands at 22.85 based on trailing twelve-month earnings.
Advertisement
In-Article Ad
Dr Reddy's Laboratories Ltd shares are currently priced at ₹1268.7, reflecting a 0.1% decline as of 13:19 IST on the National Stock Exchange (NSE). This marks the fifth consecutive day of falling prices for the pharmaceutical company. Over the past year, Dr Reddy's stock has increased by 3.99%, which is notably lower than the 4.71% decline in the NIFTY index, while the Nifty Pharma index has surged by 11.69%. Despite this recent downturn, the stock has gained approximately 4.18% over the last month. Today's trading volume reached 77.06 lakh shares, significantly higher than the average of 31.23 lakh shares over the past month. The stock's price-to-earnings (PE) ratio is currently 22.85 based on trailing twelve-month earnings.
Advertisement
In-Article Ad
The ongoing decline in Dr Reddy's stock may affect investor confidence and could influence future investment decisions in the pharmaceutical sector.
Advertisement
In-Article Ad
Reader Poll
What do you think will happen to Dr Reddy's stock in the next month?
Connecting to poll...
More about Dr Reddy's Laboratories Ltd
Read the original article
Visit the source for the complete story.